New hope for HER2-mutated lung cancer: phase 3 trial of targeted drug SHR-A1811 begins
NCT ID NCT06430437
First seen Jan 24, 2026 · Last updated Apr 23, 2026 · Updated 14 times
Summary
This study tests a new drug called SHR-A1811 against standard treatments for people with advanced or spreading non-small cell lung cancer that has a specific HER2 gene change. About 300 adults aged 18-75 who have not had prior cancer therapy will be randomly assigned to receive either SHR-A1811 or usual care. The main goal is to see if the new drug delays cancer growth better than current options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER WITH HER2- MUTATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact
Conditions
Explore the condition pages connected to this study.